This comes after notification to AstraZeneca by holland Wellness Authority.

AstraZeneca Regulatory Revise on Seroquel XR for the treating Major Depressive Disorder AstraZeneca today announced that the business has referred its software for SEROQUEL XR Extended Launch Tablets for the treating recurrent depressive episodes in adult individuals with main depressive disorder to the Committee for Medicinal Items for Human Make use of sildenafil citrate side effects suhagrasildenafil.com . This comes after notification to AstraZeneca by holland Wellness Authority , acting because the Reference Member Condition for the Mutual Acknowledgement Procedure , that the SEROQUEL XR program for MDD offers been refused. AstraZeneca believes that outcomes from the medical trial program demonstrate that SEROQUEL XR offers potential as a very important treatment option for sufferers with MDD.